NanoRepro AG Logo

NanoRepro AG

Develops and distributes rapid diagnostic self-tests for early disease detection.

NN6 | F

Overview

Corporate Details

ISIN(s):
DE0006577109
LEI:
3912008FCA63AGIMEV74
Country:
Germany
Address:
UNTERGASSE 8, 35037 MARBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NanoRepro AG is an innovative leader in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The company serves both home and professional markets, domestically and internationally. Its product portfolio is designed to provide rapid and accurate results for early disease detection and preventive healthcare. Key product categories include family planning, disease detection, food intolerances, allergies, and infectious diseases. The company's stated goal is to provide accuracy in self-diagnostics for rapid disease detection.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Annual Report
Datum:05.09.2025
German 442.2 KB
2025-08-20 14:30
Regulatory News Service
NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 Euro
German 13.2 KB
2025-08-05 14:00
Director's Dealing
NanoRepro AG: Lisa Jungst, buy
German 6.0 KB
2025-07-21 00:00
Annual / Quarterly Financial Statement
Berichtigung der Veröffentlichung vom 14.03.2025
German 15.0 KB
2025-07-18 15:00
Earnings Release
NanoRepro AG: Endgultige Jahreszahlen 2024 - NanoRepro bleibt auf Wachstumskurs
German 14.4 KB
2025-05-26 14:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-19 12:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-08 15:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-04-29 14:00
M&A Activity
NanoRepro AG: NanoRepro AG investiert in Kaltplasma-Technologie und baut ihre M…
German 11.4 KB
2025-04-16 14:00
Regulatory News Service
NanoRepro AG: NanoRepro erhalt EU-Qualitatsmanagementbescheinigung nach Verordn…
German 8.9 KB
2025-03-27 15:46
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-03-26 16:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-03-14 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 34.7 KB
2025-02-26 09:45
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-02-25 09:45
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB

Automate Your Workflow. Get a real-time feed of all NanoRepro AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NanoRepro AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-25 Stiller, Dr. Olaf Supervisory board Buy None 14,506.24 EUR
2025-02-17 Stiller, Dr. Olaf Supervisory board Buy None 18,750.00 EUR
2024-10-29 Stiller, Dr. Olaf Supervisory board Buy None 17,300.00 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,949.96 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,500.00 EUR
2024-10-21 Stiller, Dr. Olaf Supervisory board Buy None 8,750.00 EUR
2024-10-21 Stiller, Johanna Close relation Buy None 3,759.00 EUR
2024-08-30 ASS GmbH Close relation Buy None 30,644.30 EUR
2024-07-25 Stiller, Dr. Olaf Supervisory board Buy None 3,279.18 EUR
2024-07-24 Jüngst, Lisa Board Buy None 21,762.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.